Neuromyelitis optica spectrum disorders with non opticospinal manifestations as initial symptoms: a long-term observational study

被引:6
|
作者
Li, Rui [1 ]
Lu, Danli [1 ]
Li, Hao [2 ]
Wang, Yuge [1 ]
Shu, Yaqing [1 ]
Chang, Yanyu [1 ]
Sun, Xiaobo [1 ]
Lu, Zhengqi [1 ]
Qiu, Wei [1 ,3 ]
Yang, Zhi [2 ]
机构
[1] Sun Yat Sen Univ, Dept Neurol, Affiliated Hosp 3, Guangzhou, Peoples R China
[2] Maoming Peoples Hosp, Dept Neurol, 101 Weimin Rd, Maoming, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Dept Neurol, Multiple Sclerosis Ctr, Affiliated Hosp 3, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
Neuromyelitis optica spectrum disorders; Vomiting; Area postrema; Clinical outcomes; AQP4 antibody titers;
D O I
10.1186/s12883-021-02059-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Early stage neuromyelitis optica spectrum disorders (NMOSD) with non-opticospinal manifestations as initial symptoms are easily misdiagnosed; however, data on the full symptom profile are limited. Moreover, the clinical characteristics and long-term outcomes of these patients remain unknown. We sought to analyze the clinical characteristics, imaging features, and long-term outcomes of NMOSD with non-opticospinal manifestations as initial symptoms. Methods We retrospectively included relevant patients from our center. Clinical, demographic, magnetic resonance imaging, treatment, and outcome data were compared according to the non-opticospinal vs. opticospinal initial symptoms. Results We identified 43 (9.13 %) patients with non-opticospinal initial symptoms among 471 patients with NMOSD. Of these, 88.37 % developed optic neuritis/myelitis during an average follow-up period of 6.33 years. All the non-opticospinal symptoms were brain/brainstem symptoms. Most of the symptoms and associated brain lesions were reversible. These patients had a younger onset age (P < 0.001), lower serum aquaporin-4 (AQP4) antibody titers (P = 0.030), and a lower Expanded Disability Status Scale (EDSS) score at onset (P < 0.001) and follow-up (P = 0.041) than NMOSD patients with opticospinal initial symptoms. In addition, EDSS scores reached 3.0 (indicating moderate disability) later than in patients with opticospinal initial symptoms (P = 0.028). Conclusions Patients with NMOSD with non-opticospinal initial symptoms have a younger onset age, lower serum AQP4 antibody titers, and better clinical outcomes.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Neuromyelitis optica spectrum disorders with multiple brainstem manifestations: a case report
    Yao Li
    Bin Jiang
    Bin Chen
    Mingxia Zhao
    Chunlai Zhou
    Shuhui Wang
    Jimei Li
    Ruijin Wang
    Neurological Sciences, 2016, 37 : 309 - 313
  • [22] Neuromyelitis optica spectrum disorders with multiple brainstem manifestations: a case report
    Li, Yao
    Jiang, Bin
    Chen, Bin
    Zhao, Mingxia
    Zhou, Chunlai
    Wang, Shuhui
    Li, Jimei
    Wang, Ruijin
    NEUROLOGICAL SCIENCES, 2016, 37 (02) : 309 - 313
  • [23] Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
    Kuempfel, Tania
    Giglhuber, Katrin
    Aktas, Orhan
    Ayzenberg, Ilya
    Bellmann-Strobl, Judith
    Haeussler, Vivien
    Havla, Joachim
    Hellwig, Kerstin
    Huemmert, Martin W.
    Jarius, Sven
    Kleiter, Ingo
    Klotz, Luisa
    Krumbholz, Markus
    Paul, Friedemann
    Ringelstein, Marius
    Ruprecht, Klemens
    Senel, Makbule
    Stellmann, Jan-Patrick
    Bergh, Florian Then
    Trebst, Corinna
    Tumani, Hayrettin
    Warnke, Clemens
    Wildemann, Brigitte
    Berthele, Achim
    JOURNAL OF NEUROLOGY, 2024, 271 (01) : 141 - 176
  • [24] Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management
    Tania Kümpfel
    Katrin Giglhuber
    Orhan Aktas
    Ilya Ayzenberg
    Judith Bellmann-Strobl
    Vivien Häußler
    Joachim Havla
    Kerstin Hellwig
    Martin W. Hümmert
    Sven Jarius
    Ingo Kleiter
    Luisa Klotz
    Markus Krumbholz
    Friedemann Paul
    Marius Ringelstein
    Klemens Ruprecht
    Makbule Senel
    Jan-Patrick Stellmann
    Florian Then Bergh
    Corinna Trebst
    Hayrettin Tumani
    Clemens Warnke
    Brigitte Wildemann
    Achim Berthele
    Journal of Neurology, 2024, 271 : 141 - 176
  • [25] Long term Mortality in Neuromyelitis Optica Spectrum Disorder
    Collazo, Iris Marin
    Weinshenker, Brian
    Nasr, Zahra
    Lopez, Alfonso
    NEUROLOGY, 2018, 90
  • [26] Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study
    Shaygannejad, V.
    Fayyazi, E.
    Badihian, S.
    Mirmosayyeb, O.
    Manouchehri, N.
    Ashtari, F.
    Asgari, N.
    JOURNAL OF NEUROLOGY, 2019, 266 (03) : 642 - 650
  • [27] Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study
    V. Shaygannejad
    E. Fayyazi
    S. Badihian
    O. Mirmosayyeb
    N. Manouchehri
    F. Ashtari
    N. Asgari
    Journal of Neurology, 2019, 266 : 642 - 650
  • [28] Long-term efficacy and safety of rituximab in the treatment of neuromyelitis Optica Spectrum disorder
    Hayes, Michael T. G.
    Adam, Robert J.
    McCombe, Pamela A.
    Walsh, Michael
    Blum, Stefan
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2024, 10 (02)
  • [29] Long-term treatment of neuromyelitis optica with rituximab
    Aboul-Enein, F.
    Rauschka, H.
    Kuenz, B.
    Di Pauli, F.
    Schrattbauer, K.
    Krugluger, W.
    Reindl, M.
    Berger, T.
    Kristoferitsch, W.
    MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S212 - S212
  • [30] Neuromyelitis Optica Spectrum Disorder: Disease Course and Long-Term Visual Outcome
    Brody, Judith
    Hellmann, Mark A.
    Marignier, Romain
    Lotan, Itay
    Stiebel-Kalish, Hadas
    JOURNAL OF NEURO-OPHTHALMOLOGY, 2016, 36 (04) : 356 - 362